ArticleMolecular cell2023
A lncRNA from the FTO locus acts as a suppressor of the m
Open access · hybridAbstract read
In one paragraph
Article in Molecular cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 41 citations in OpenAlex.
- Lian-Jia-San-Jie formula suppresses non-small cell lung cancer via FTO-dependent mBiochemistry and biophysics reports · 2026Article
- RBM protein family: Focusing on the occurrence, progression and treatment of cancer.Medical oncology (Northwood, London, England) · 2026Review
- RNA modifications in cancer: regulators of tumor evolution and therapeutic response.Molecular cancer · 2026Review
- N6-Methyladenosine RNA Methylation: A Key Regulator in Male Reproductive Disorders and Urological Cancers.The world journal of men's health · 2026Review
- LFPM inhibition of RING1-mediated p53Cell death and differentiation · 2026Article
- RNA modifications and epigenetic regulation in plants.aBIOTECH · 2026Review
- RBM15 in diseases: Molecular mechanisms and clinical opportunities from RNA mGenes & diseases · 2026Review
- Targeting the RNA-binding motif protein 15 suppresses prostate cancer progression and hormone therapy resistance by promoting androgen receptor degradation.Molecular biomedicine · 2026Article
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation.Current medicinal chemistry · 2026Article
- The methylation pattern of osimertinib resistance: prospects for diagnosis and treatment of NSCLC.Frontiers in oncology · 2026Review
- Deacetylation of ACLY Mediates RNA MAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Impact of NbioRxiv : the preprint server for biology · 2025Article
- mMolecules (Basel, Switzerland) · 2025Review
- Fto-mediated mJournal of biomedical science · 2025Article
- LncRNA938/ TAF9/TTK axis promotes EMT and serves as a therapeutic target in hepatoblastoma.Journal of translational medicine · 2025Article
- Emerging implications of N6-methyladenosine in prostate cancer progression and treatment.Cell death discovery · 2025Review
- Potential regulatory role of the mActa biochimica et biophysica Sinica · 2025Review
- FTO-mediated mClinical and translational medicine · 2025Article
- Biological roles of enhancer RNA m6A modification and its implications in cancer.Cell communication and signaling : CCS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 3 countries.
Jianong ZhangDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai 200080, China. Electronic address: hugebox@qq.com.
Jiangbo WeiDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA.
Rui SunDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Haoyue ShengDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Kai YinDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Department of General Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang 212002, China.
Yunqian PanDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Rafael JimenezDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Sujun ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Xiao-Long CuiDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA.
Zhongyu ZouDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA.
Zhiying YuePrecision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.
Michael J EmchDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
John R HawseDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Liguo WangDepartment of Computation Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Housheng Hansen HePrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada.
Shujie XiaDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai 200080, China.
Bangmin HanDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Hongkou District, Shanghai 200080, China.
Chuan HeDepartment of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA; Howard Hughes Medical Institute, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA. Electronic address: chuanhe@uchicago.edu.
Haojie HuangDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: huang.haojie@mayo.edu.
Mayo Clinic · USShanghai First People's Hospital · CNHoward Hughes Medical Institute · USUniversity Health Network · CAUniversity of Chicago · US
Funding
Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6MRole of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancerR01CA130908 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HUANG, HAOJIE · 2010 to 2021
$3.5MNext Generation Rat Models of ER+ Breast CancerR01CA271498 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Yi Li, Xiang Zhang · 2022 to 2026
$3.1MDirect Oxidative Nucleic Acids DemethylationR01ES030546 · NIEHS · UNIVERSITY OF CHICAGO · PI HE, CHUAN · 2019 to 2023
$1.9MCooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesisR01CA271486 · NCI · MAYO CLINIC ROCHESTER · PI Liewei Wang · 2022 to 2026
$1.8MMechanism and role of aberrant AR activity in castration-resistant prostate cancerR01CA203849 · NCI · MAYO CLINIC ROCHESTER · PI HUANG, HAOJIE · 2018 to 2022
$1.8MNCI NIH HHS R01 CA130908NCI NIH HHS R01 CA203849NCI NIH HHS R01 CA271486NCI NIH HHS R01 CA271498NIEHS NIH HHS P30 ES027792NIEHS NIH HHS R01 ES030546
Abstract
N
Indexed as
NeoplasmsRNA, Long NoncodingAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOAnimalsMaleMethyltransferasesMiceRNA, MessengerTumor Suppressor Protein p53AdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOFTO protein, mouseMethyltransferasesRNA, Long NoncodingRNA, MessengerTumor Suppressor Protein p53FTOFTO-IT1lncRNAm(6)AMETTL14METTL3N(6)-methyladenosinep53prostate cancerRBM15
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.